Reference(s)
Click here to return to the Reference Table

Descriptor: Mutation of Met


Acute Myelogenous Leukemia

Adult T Cell Leukemia

Bladder

Breast

Reference Number: 651
Finegold DN, Schacht V, Kimak MA, Lawrence EC, Foeldi E, Karlsson JM, Baty CJ, Ferrell RE. HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol. 6, 65-8 (2008)
PubMed link      E-mail link

Reference Number: 1340
Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci U S A. 110, E1301-10 (2013)
PubMed link      E-mail link

Reference Number: 1569
Tilch E, Seidens T, Cocciardi S, Reid LE, Byrne D, Simpson PT, Vargas AC, Cummings MC, Fox SB, Lakhani SR, Chenevix Trench G. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast Cancer Res Treat. 143, 385-92 (2014)
PubMed link      E-mail link

Reference Number: 1753
de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer. 14, 468-74 (2014)
PubMed link      E-mail link

Cervical

Cholangiocarcinoma

Chronic Myeloid Leukemia

Colorectal

Reference Number: 1327
Gawlick U, Lu KC, Douthit MA, Diggs BS, Schuff KG, Herzig DO, Tsikitis VL. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry. Am J Surgery 205, 608-12; discussion 612 (2013)
PubMed link      E-mail link

Reference Number: 1390
Jiang L1, Huang J, Morehouse C, Zhu W, Korolevich S, Sui D, Ge X, Lehmann K, Liu Z, Kiefer C, Czapiga M, Su X, Brohawn P, Gu Y, Higgs BW, Yao Y. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. Cancer Genet. 206, 330-9 (2013)
PubMed link      E-mail link

Endometrial

Esophogeal

Reference Number: 1610
Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 5, 1837-45 (2014)
PubMed link      E-mail link

Gastric

Reference Number: 45
Lee, J. H. et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19, 4947-53. (2000).
PubMed link      E-mail link

Reference Number: 726
Resorlu B, Baltaci S, Resorlu M, Kankaya D, Savas B. Coexistence of papillary renal cell carcinoma and gastrointestinal stromal tumor in a case. Turk J Gastroenterol. 18, 47-9 (2007)
PubMed link      E-mail link

Reference Number: 1610
Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 5, 1837-45 (2014)
PubMed link      E-mail link

Glioblastomas/Astrocytomas

Reference Number: 683
Moon YW, Weil RJ, Pack SD, Park WS, Pak E, Pham T, Karkera JD, Kim HK, Vortmeyer AO, Fuller BG, Zhuang Z. Missense mutation of the MET gene detected in human glioma. Mod Pathol13, 973-7 (2000)
PubMed link      E-mail link

Reference Number: 1883
Navis AC, van Lith SA, van Duijnhoven SM, de Pooter M, Yetkin-Arik B, Wesseling P, Hendriks WJ, Venselaar H, Timmer M, van Cleef P, van Bergen En Henegouwen P, Best MG, Wurdinger TD, Tops BB, Leenders WP. Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathol. 130, 131-44 (2015)
PubMed link      E-mail link

Head and Neck

Reference Number: 57
Di Renzo, M. F. et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19, 1547-55 (2000).
PubMed link      E-mail link

Reference Number: 968
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021-31 (2009)
PubMed link      E-mail link

Reference Number: 1532
Lacroix L, Post SF, Valent A, Melkane AE, Vielh P, Egile C, Castell C, Larois C, Micallef S, Saulnier P, Goulaouic H, Lefebvre AM, Temam S. MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma. PLoS One. 9, e84319 (2014)
PubMed link      E-mail link

Kaposi's Sarcoma

Kidney

Reference Number: 64
Jeffers, M. et al. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 95, 14417-22 (1998).
PubMed link      E-mail link

Reference Number: 65
Lorenzato, A. et al. d invasion. Cancer Res 62, 7025-30 (2002).
PubMed link      E-mail link

Reference Number: 66
Olivero, M. et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 82, 640-3 (1999).
PubMed link      E-mail link

Reference Number: 67
Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16, 68-73 (1997).
PubMed link      E-mail link

Reference Number: 68
Schmidt, L. et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58, 1719-22 (1998).
PubMed link      E-mail link

Reference Number: 69
Schmidt, L. et al. . Oncogene 18, 2343-50. (1999).
PubMed link      E-mail link

Reference Number: 276
Michieli P, Basilico C, Pennacchietti S, Maffe A, Tamagnone L, Giordano S, Bardelli A, Comoglio PM. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18:5221-31 (1999).
PubMed link      E-mail link

Reference Number: 277
Maritano D, Accornero P, Bonifaci N, Ponzetto C. Two mutations affecting conserved residues in the Met receptor operate via different mechanisms. Oncogene 19:1354-61 (2000).
PubMed link      E-mail link

Reference Number: 278
Chiara F, Michieli P, Pugliese L, Comoglio PM. Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity. J Biol Chem. 278, 29352-8 (2003)
PubMed link      E-mail link

Reference Number: 279

Miller M, Ginalski K, Lesyng B, Nakaigawa N, Schmidt L, Zbar B. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins. 44, 32-43 (2001)

PubMed link      E-mail link

Reference Number: 280
Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, Warren MB, Choyke PL, Torres-Cabala CA, Merino MJ, Brunet J, Berez V, Borras J, Sesia G, Middelton L, Phillips JL, Stolle C, Zbar B, Pautler SE, Linehan WM. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 172, 1256-61 (2004)
PubMed link      E-mail link

Reference Number: 330
Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, Birchmeier C, Swiatek P, Bronson R, Vande Woude G.  Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 101, 17198-203 (2004)


PubMed link      E-mail link

Reference Number: 335
Prat E, Bernués M, Del Rey J, Camps J, Ponsa I, Algaba F, Egozcue J, Caballín MR, Gelabert A, Miró R. Common pattern of unusual chromosome abnormalities in hereditary papillary renal carcinoma. Cancer Genet Cytogenet. 164, 142-7 (2006)
PubMed link      E-mail link

Reference Number: 340
Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23, 5387-93 (2004)
PubMed link      E-mail link

Reference Number: 634
Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 283, 2675-83 (2008)
PubMed link      E-mail link

Reference Number: 638
Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol. 33, 271-6 (2008)
PubMed link      E-mail link

Reference Number: 686
Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer. 44, 641-51. (2008) Epub 2008 Mar 4

PubMed link      E-mail link

Reference Number: 726
Resorlu B, Baltaci S, Resorlu M, Kankaya D, Savas B. Coexistence of papillary renal cell carcinoma and gastrointestinal stromal tumor in a case. Turk J Gastroenterol. 18, 47-9 (2007)
PubMed link      E-mail link

Reference Number: 929
Lim JC, Wojcik EM. Fine-needle aspiration cytology of papillary renal cell carcinoma: the association with concomitant secondary malignancies. Diagn Cytopathol. 34, 797-800 (2006)
PubMed link      E-mail link

Reference Number: 981
Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A. 94, 11445-50 (1997)
PubMed link      E-mail link

Reference Number: 986
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

Reference Number: 1023
Lindor NM, Dechet CB, Greene MH, Jenkins RB, Zincke MT, Weaver AL, Wilson M, Zincke H, Liu W. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test. 5, 101-6 (2001)
PubMed link      E-mail link

Reference Number: 1262
Wadt KA, Gerdes AM, Hansen TV, Toft BG, Friis-Hansen L, Andersen MK. Novel germline c-MET mutation in a family with hereditary papillary renal carcinoma. Fam Cancer. 11, 535-7 (2012)
PubMed link      E-mail link

Reference Number: 1378
Harshman LC1, Choueiri TK. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J. 19, 316-23 (2013)
PubMed link      E-mail link

Reference Number: 1547
Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 21, 81-90 (2014)
PubMed link      E-mail link

Reference Number: 1604
Albiges L, Guegan J, Le Formal A, Verkarre V, Rioux-Leclercq N, Sibony M, Bernhard JC, Camparo P, Merabet Z, Molinie V, Allory Y, Orear C, Couvé S, Gad S, Patard JJ, Escudier B. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res. 20, 3411-21 (2014)
PubMed link      E-mail link

Reference Number: 1643
Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet. 47, 13-21 (2015)
PubMed link      E-mail link

Reference Number: 1868
Garcia-Donas J, Rodriguez-Moreno JF, Romero-Laorden N, Rodriguez-Antona C. Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization. Urol Oncol. 33, 179-86 (2015)
PubMed link      E-mail link

Leiomyosarcoma

Liver

Reference Number: 77
Park, W. S. et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59, 307-10 (1999).
PubMed link      E-mail link

Lung

Reference Number: 225

Ma, P.C. et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272-81 (2003).


PubMed link      E-mail link

Reference Number: 333
Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res65, 1479-88 (2005)
PubMed link      E-mail link

Reference Number: 341
Zaffaroni D, Spinola M, Galvan A, Falvella FS, Pazzaglia S, Saran A, Mancuso MT, Galbiati F, Pignatiello C, Cabrera W, Ibanez O, Manenti G, Dragani TA. Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis. Oncogene  24, 1084-90 (2005)
PubMed link      E-mail link

Reference Number: 388
Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, Holcomb T, Pujara K, Stinson J, Fu L, Severin C, Rangell L, Schwall R, Amler L, Wickramasinghe D, Yauch R. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 66, 283-9 (2006)
PubMed link      E-mail link

Reference Number: 440
Tengs T, Lee JC, Guillermo Paez J, Zhao X, Laframboise T, Giannoukos G, Thomas RK. A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. Cancer Lett. 239, 227-33 (2006)
PubMed link      E-mail link

Reference Number: 641
Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol. 3, 331-9 (2008)
PubMed link      E-mail link

Reference Number: 691
Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 99, 2280-5 (2008)
PubMed link      E-mail link

Reference Number: 707

Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol. 4, 5-11 (2009)

PubMed link      E-mail link

Reference Number: 708
Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 47, 1025-37 (2008)
PubMed link      E-mail link

Reference Number: 898
Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 3, 305-13 (2010)
PubMed link      E-mail link

Reference Number: 899
Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, Sattler M, Vokes EE, Wang YC, Salgia R. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 5, e8972 (2010)
PubMed link      E-mail link

Reference Number: 986
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

Reference Number: 1030
Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H, Nakagawa K. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 6, 1624-31 (2011)
PubMed link      E-mail link

Reference Number: 1087
Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, Ferguson MK, Natarajan V, Wang YC, Garcia JG, Vokes EE, Salgia R. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 15, 5714-23 (2009)
PubMed link      E-mail link

Reference Number: 1088
Salgia R. Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol. 36(2 Suppl 1), S52-8 (2009)
PubMed link      E-mail link

Reference Number: 1152
Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, Flacco A, Giuffrida D, Sidoni A, Crinò L. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol. 69, 1289-99 (2012)
PubMed link      E-mail link

Reference Number: 1162
Gumustekin M, Kargi A, Bulut G, Gozukizil A, Ulukus C, Oztop I, Atabey N. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res. 18, 209-18 (2012)
PubMed link      E-mail link

Reference Number: 1289
Voortman J, Harada T, Chang RP, Killian JK, Suuriniemi M, Smith WI, Meltzer PS, Lucchi M, Wang Y, Giaccone G. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. Curr Pharm Des. 19, 833-40 (2013)
PubMed link      E-mail link

Reference Number: 1415
Jiang L1, Huang J, Morehouse C, Zhu W, Korolevich S, Sui D, Ge X, Lehmann K, Liu Z, Kiefer C, Czapiga M, Su X, Brohawn P, Gu Y, Higgs BW, Yao Y. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. Cancer Genet. 206, 330-9 (2013)
PubMed link      E-mail link

Reference Number: 1474
Xia N, An J, Jiang QQ, Li M, Tan J, Hu CP. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. Exp Lung Res. 39, 328-35 (2013)
PubMed link      E-mail link

Reference Number: 1500
Boland JM, Jang JS, Li J, Lee AM, Wampfler JA, Erickson-Johnson MR, Soares I, Yang P, Jen J, Oliveira AM, Yi ES. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol. 8, 574-81 (2013)
PubMed link      E-mail link

Reference Number: 1673
Tuononen K, Kero M, Mäki-Nevala S, Sarhadi VK, Tikkanen M, Wirtanen T, Rönty M, Knuuttila A, Knuutila S. ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients. Genes Chromosomes Cancer. 53, 895-901 (2014)
PubMed link      E-mail link

Reference Number: 1674
Vieira T, Antoine M, Ruppert AM, Fallet V, Duruisseaux M, Giroux Leprieur E, Poulot V, Rabbe N, Sclick L, Beau-Faller M, Lacave R, Lavole A, Cadranel J, Wislez M. Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. Lung Cancer. 85, 276-81 (2014)
PubMed link      E-mail link

Reference Number: 1676
Bordi P, Tiseo M, Barbieri F, Bavieri M, Sartori G, Marchetti A, Buttitta F, Bortesi B, Ambrosini-Spaltro A, Gnetti L, Silini EM, Ardizzoni A, Rossi G. Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients. Lung Cancer. 86, 324-8 (2014)
PubMed link      E-mail link

Reference Number: 1773
Dhanasekaran SM, Balbin OA, Chen G, Nadal E, Kalyana-Sundaram S, Pan J, Veeneman B, Cao X, Malik R, Vats P, Wang R, Huang S, Zhong J, Jing X, Iyer M, Wu YM, Harms PW, Lin J, Reddy R, Brennan C, Palanisamy N, Chang AC, Truini A, Truini M, Robinson DR, Beer DG, Chinnaiyan AM. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun. 5, 5893 (2014)
PubMed link      E-mail link

Reference Number: 1778
Cao X, Hong X, Jia X, Zhang L, Chen G. Single-nucleotide polymorphism rs41736 located in MET was significantly associated with prognosis of small cell lung cancer patients. Med Oncol. 31, 333 (2014)
PubMed link      E-mail link

Reference Number: 1794
Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, Ladanyi M. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 5, 842-9 (2015)
PubMed link      E-mail link

Lymphomas

Reference Number: 339
Graveel CR, London CA, Vande Woude GF. A mouse model of activating Met mutations. Cell Cycle4, 518-20. Epub 2005 (2005)


PubMed link      E-mail link

Melanoma

Mesothelioma

Reference Number: 986
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

MFH/Fibrosarcoma

Multiple Myeloma

Nasopharyngeal

Osteosarcoma

Reference Number: 411
Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM, Di Renzo MF. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 66, 4750-7 (2006)
PubMed link      E-mail link

Ovarian

Reference Number: 107
Tanyi, J., Tory, K., Rigo, J., Jr., Nagy, B. & Papp, Z. Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*. Pathol Oncol Res 5, 187-91 (1999).
PubMed link      E-mail link

Reference Number: 1337
Biscuola M, Van de Vijver K, Castilla MÁ, Romero-Pérez L, López-García MÁ, Díaz-Martín J, Matias-Guiu X, Oliva E, Palacios Calvo J. Oncogene alterations in endometrial carcinosarcomas. Hum Pathol. 44, 852-9 (2013)
PubMed link      E-mail link

Pancreas/Gall Bladder

Prostate

Rhabdomyosarcoma

Synovial Sarcoma

Thyroid

Reference Number: 384
Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, Nupponen NN, Franssila K, Joensuu H. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol. 29, 544-9 (2005)
PubMed link      E-mail link

Wilms' Tumor